Humanigen soars as Q1 loss narrows, provides COVID-19 therapy update

Humanigen

06/05/2022 18:17

** Shares of drug developer  HGEN.O  soar 25% to $2.31 -
second biggest pct gainer across U.S. exchanges in afternoon
trade 
    ** HGEN's Q1 net loss narrows to $21.3 mln, or $0.32 per
share, vs $65.6 mln, or $1.25 per share, a year earlier, on
lower research and development expenses  urn:newsml:reuters.com:*:nBwZsgYha
    ** Co also said it had productive meeting with FDA regarding
its experimental COVID-19 therapy, lenzilumab, where both
parties agreed on data and analysis to be included in amendment
to company's EUA application for drug
    ** FDA had declined granting authorization for lenzilumab to
treat newly hospitalized COVID-19 patients in Sept and HGEN had
said data from an ongoing late-stage trial could provide more
evidence on the drug's benefits
    ** HGEN expects data from study in Q2, with an amendment to
its EUA submission planned to follow
    ** Stock down 38% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))